rs10516173 - STK32B
Magnitude 4.5 · 1 study on file
Reported associations
-
Genome-wide Association Study of Virologic Response with Efavirenz- or Abacavir-containing Regimens in AIDS Clinical Trials Group Protocols - Unknown journal (n.d.) · Unknown authors · PubMed 25461247
ABSTRACT: Background Efavirenz and abacavir are components of recommended first-line regimens for human immunodeficiency virus (HIV)-1 infection. We used genome-wide genotyping and clinical data to explore genetic associations with virologic failure among subjects randomized to efavirenz- or abacavir-containing regimens in AIDS Clinical Trials Group (ACTG) protocols. Methods Virologic response and genome-wide genotype data were available from treatment-naive subjects randomized to efavirenz-containing (n=1,596) or abacavir-containing (n=786) regimens in ACTG protocols 384, A5142, A5095, and A5202. Results Meta-analysis of association results across race/ethnic groups showed no genome-wide significant associations (p<5×10−8) with virologic response for either efavirenz or abacavir. Our s
Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.
Lifestyle context
Concrete actions anchored to the cited research. We do not prescribe, we describe.
Discuss with your doctor
-
STK32B variant and abacavir therapy response in HIV Moderate
The rs10516173 T allele associates with increased virologic failure in patients receiving abacavir-containing antiretroviral therapy
Discuss this genetic finding with your HIV treatment specialist if considering abacavir-based therapy